Chiara Nicolazzo

TL;DR: The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer.

TL;DR: The persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape, and patients could be dichotomized into two groups based PD- L1 expression on C TCs, which suggests that the persistence ofPD-L2 negative CTCS all obtained a clinical benefit, while patients with PD-CTCs all experienced progressive disease.

TL;DR: The presence of mesenchymal markers on CTC more accurately predicted worse prognosis than the expression of cytokeratins alone and assays targeting epithelial antigens may miss the most invasive cell population.

TL;DR: The detection of CTC in this setting of disease may allow to distinguish patients with high risk of recurrence from those with highrisk of progression, as well as to early identify patients candidate for adjuvant treatment.

TL;DR: Evidence is provided that CTC analyses can identify patients with Stage I bladder cancer who have already a systemic disease at diagnosis and might, therefore, potentially benefit from systemic treatment.